Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Takeda Pharmaceutical Co Ltd ADR is a drug manufacturers-specialty & generic business based in the US. Takeda Pharmaceutical Co Ltd ADR shares (TAK) are listed on the NYSE and all prices are listed in US Dollars. Takeda Pharmaceutical Co Ltd ADR employs 47,347 staff and has a trailing 12-month revenue of around $3.7 trillion.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $15.74 |
|---|---|
| 52-week range | $12.28 - $16.30 |
| 50-day moving average | $15.25 |
| 200-day moving average | $14.19 |
| Wall St. target price | $18.05 |
| PE ratio | 30.3846 |
| Dividend yield | $180 (4.15%) |
| Earnings per share (TTM) | $0.52 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $15.74 from 2023-02-02
| 1 week (2023-01-27) | -1.81% |
|---|---|
| 1 month (2023-01-03) | -0.13% |
| 3 months (2022-11-03) | 20.06% |
| 6 months (2022-08-03) | 13.32% |
| 1 year (2022-02-03) | 9.00% |
|---|---|
| 2 years (2021-02-03) | -9.70% |
| 3 years (2020-02-03) | 19.36 |
| 5 years (2018-02-02) | 29.515 |
Valuing Takeda Pharmaceutical Co Ltd ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Takeda Pharmaceutical Co Ltd ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Takeda Pharmaceutical Co Ltd ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Takeda Pharmaceutical Co Ltd ADR shares trade at around 30x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Takeda Pharmaceutical Co Ltd ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5932. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Takeda Pharmaceutical Co Ltd ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Takeda Pharmaceutical Co Ltd ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1,048.8 billion.
The EBITDA is a measure of a Takeda Pharmaceutical Co Ltd ADR's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $3,749.4 billion |
|---|---|
| Operating margin TTM | 13.16% |
| Gross profit TTM | $2,441.7 billion |
| Return on assets TTM | 2.27% |
| Return on equity TTM | 3.54% |
| Profit margin | 5.69% |
| Book value | $2,159.04 |
| Market capitalisation | $49.2 billion |
TTM: trailing 12 months
Dividend payout ratio: 1.75% of net profits
Recently Takeda Pharmaceutical Co Ltd ADR has paid out, on average, around 1.75% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 4.15% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Takeda Pharmaceutical Co Ltd ADR shareholders could enjoy a 4.15% return on their shares, in the form of dividend payments. In Takeda Pharmaceutical Co Ltd ADR's case, that would currently equate to about $180 per share.
While Takeda Pharmaceutical Co Ltd ADR's payout ratio might seem low, this can signify that Takeda Pharmaceutical Co Ltd ADR is investing more in its future growth.
Takeda Pharmaceutical Co Ltd ADR's most recent dividend payout was on 14 December 2009. The latest dividend was paid out to all shareholders who bought their shares by 28 September 2022 (the "ex-dividend date").
Over the last 12 months, Takeda Pharmaceutical Co Ltd ADR's shares have ranged in value from as little as $12.28 up to $16.3. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Takeda Pharmaceutical Co Ltd ADR's is 0.7271. This would suggest that Takeda Pharmaceutical Co Ltd ADR's shares are less volatile than average (for this exchange).
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc. ; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc. , and Ovid Therapeutics Inc. ; and collaboration with Evox Therapeutics Ltd.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
